From the Research
The management of keratoacanthoma (KA) should prioritize intralesional 5-fluorouracil (5-FU) as a first-line treatment option, given its effectiveness and faster results compared to other treatments, as evidenced by the most recent study 1. The goal of KA management is to achieve complete removal of the tumor while minimizing morbidity, mortality, and impact on quality of life.
- Intralesional 5-FU has been shown to be effective in treating KA, with a study demonstrating that it may give faster results compared to intralesional methotrexate 1.
- Surgical excision is also a viable option, particularly for larger lesions or those that do not respond to intralesional treatments, as it allows for histopathological examination to rule out squamous cell carcinoma 2, 3.
- Other treatment options, such as topical 5% imiquimod cream, oral retinoids, and cryotherapy, may be considered for smaller lesions or for patients who are poor surgical candidates 4, 5, 2.
- Close follow-up is essential regardless of the treatment approach to ensure complete resolution and to monitor for potential complications or recurrence 3.
- The choice of treatment should be individualized based on the patient's specific needs and circumstances, taking into account factors such as lesion size, location, and the patient's overall health status.